 BEIJING, April 20, 2021 PRNewswire -- China Biologic Products Holdings, Inc. NASDAQ: CBPO, China Biologic or the Company, a leading fully integrated plasma-based biopharmaceutical company in China, today announced the completion of its merger the Merger with CBPO Group Limited Merger Sub, a wholly owned subsidiary of CBPO Holdings Limited Parent, pursuant to the previously announced agreement and plan of merger, dated as of November 19, 2020 the Merger Agreement among the Company, Parent and Merger Sub. As a result of the Merger, the Company became a wholly owned subsidiary of Parent and will cease to be a publicly traded company. 